On September 10, 2019 SEngine Precision Medicine and Atomwise, Inc. reported a joint venture to accelerate novel oncology drug discovery utilizing the unique platform technologies each company has validated through years of development (Press release, SEngine Precision Medicine, SEP 10, 2019, View Source [SID1234539416]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SEngine Precision Medicine will provide the joint venture with validated gene targets that are essential for the growth of mutant cancer cells. Atomwise will use its AI technology to discover and develop inhibitor compounds against these targets. SEngine will evaluate and validate these novel compounds using its proprietary PARIS Test to perform "in vitro clinical trials" which can screen hundreds of candidate drugs and drug combinations simultaneously against living tumors in the form of patient-derived organoids. Atomwise will use its AI technology to optimize possible drug candidates based upon data from SEngine’s "in vitro clinical trials." This unique approach is expected to rapidly advance the development of clinical candidates and greatly reduce time and costs.

"The combined capabilities of this collaboration create a model for the next generation of drug discovery to decrease time to market and lower the cost of clinical trials," said Dr. Carla Grandori, SEngine Precision Medicine Founder and CEO. She continued, "The process from discovering a promising small molecule to validation for a clinical trial candidate may now be accomplished at a fraction of the cost and time required of current efforts which may take up to ten years."

"Precision medicine for oncology requires technology that can provide a deep understanding of the biology of individual cancers and technology that can identify and evaluate potential drugs for individual cancers," said Dr. Abraham Heifets, CEO and Co-Founder of Atomwise. "This joint venture creates a path toward the development of small molecule therapies that are personalized for each cancer patient."